MetaVia expands vanoglipel patent portfolio protection into 2035

Reuters03-12 21:04
MetaVia expands vanoglipel patent portfolio protection into 2035

MetaVia said its global intellectual property portfolio for vanoglipel includes 48 granted and pending patents across three patent families. The company said the patents cover the compound, manufacturing methods, and pharmaceutical compositions. MetaVia said the portfolio includes the U.S., Europe, Japan, China and other countries, with protection into 2035 unless extended further. President and CEO Hyung Heon Kim commented on the company’s intellectual property strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY08098) on March 12, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment